Chongqing Genrix Biopharmaceutical (688443.SH) Secures Clinical Trial Approval for Sleridimab Injection

Stock News07-29

Chongqing Genrix Biopharmaceutical Co., Ltd. announced its investigational drug Sleridimab Injection has received clinical trial authorization from regulatory authorities. This monoclonal antibody therapy advances the company's immunology pipeline targeting autoimmune disorders. The Shanghai-listed biopharmaceutical firm specializes in novel antibody development with multiple candidates in preclinical and clinical stages. Approval enables Phase 1 human trials evaluating safety and pharmacokinetics. This milestone follows Genrix's strategic focus on innovative biologics addressing unmet medical needs across inflammatory and oncological indications. No trial timelines or specific indications were disclosed in the regulatory filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150015479?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150015479","market":"hk","top_or_hot":-1,"title":"Chongqing Genrix Biopharmaceutical (688443.SH) Secures Clinical Trial Approval for Sleridimab Injection","media":"Stock News","content":"<p>Chongqing Genrix Biopharmaceutical Co., Ltd. announced its investigational drug Sleridimab Injection has received clinical trial authorization from regulatory authorities. This monoclonal antibody therapy advances the company's immunology pipeline targeting autoimmune disorders. The Shanghai-listed biopharmaceutical firm specializes in novel antibody development with multiple candidates in preclinical and clinical stages. Approval enables Phase 1 human trials evaluating safety and pharmacokinetics. This milestone follows Genrix's strategic focus on innovative biologics addressing unmet medical needs across inflammatory and oncological indications. No trial timelines or specific indications were disclosed in the regulatory filing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chongqing Genrix Biopharmaceutical (688443.SH) Secures Clinical Trial Approval for Sleridimab Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChongqing Genrix Biopharmaceutical (688443.SH) Secures Clinical Trial Approval for Sleridimab Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-07-29 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chongqing Genrix Biopharmaceutical Co., Ltd. announced its investigational drug Sleridimab Injection has received clinical trial authorization from regulatory authorities. This monoclonal antibody therapy advances the company's immunology pipeline targeting autoimmune disorders. The Shanghai-listed biopharmaceutical firm specializes in novel antibody development with multiple candidates in preclinical and clinical stages. Approval enables Phase 1 human trials evaluating safety and pharmacokinetics. This milestone follows Genrix's strategic focus on innovative biologics addressing unmet medical needs across inflammatory and oncological indications. No trial timelines or specific indications were disclosed in the regulatory filing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688443","symbol_name":"智翔金泰","start_time":0,"source_url":"","article_id":"1150015479","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150015479","pubTimestamp":1753778662,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Chongqing Genrix Biopharmaceutical Co., Ltd. announced its investigational drug Sleridimab Injection has received clinical trial authorization from regulatory authorities. This monoclonal antibody...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688443":"智翔金泰","03347":"泰格医药","BK1583":"高瓴概念","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK0239":"医药制造"},"translate_title":"重庆Genrix生物制药（688443.SH）获得斯乐迪单抗注射液临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688443":1,"03347":1},"content_text":"Chongqing Genrix Biopharmaceutical Co., Ltd. announced its investigational drug Sleridimab Injection has received clinical trial authorization from regulatory authorities. This monoclonal antibody therapy advances the company's immunology pipeline targeting autoimmune disorders. The Shanghai-listed biopharmaceutical firm specializes in novel antibody development with multiple candidates in preclinical and clinical stages. Approval enables Phase 1 human trials evaluating safety and pharmacokinetics. This milestone follows Genrix's strategic focus on innovative biologics addressing unmet medical needs across inflammatory and oncological indications. No trial timelines or specific indications were disclosed in the regulatory filing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150015479","isCrawlerRequest":true}